Ostia Sciences Inc.

About Ostia Sciences Inc.

Ostia Sciences Inc. is a biotech startup focused on identifying and developing beneficial microbes to combat infectious diseases and enhance immune function. Their mission is to advance healthcare through innovative microbiome-based solutions, with breakthrough discoveries like Salivaricin 10, the world's first phosphorylated antibiotic.

Products & Services

Salivaricin 10:The world's first phosphorylated lantibiotic, offering therapeutic activity against oral and respiratory tract infections.

Streptococcus salivarius SALI-10:A probiotic bacterium identified for its health-promoting properties.

Bacteriocin-Producing Probiotics:Innovative probiotics that produce antibiotic-like molecules (bacteriocins) with drug-like properties for microbiome therapies.

Biotherapeutic Drugs:Patented drugs utilizing phosphorylated lantibiotics with dual antimicrobial and immunomodulation bioactivities for disease prevention and treatment.

Specialties

Human Microbiome Research Beneficial Microbes Identification Biotherapeutic Drug Development Microbiome-Based Therapies Phosphorylated Lantibiotics Infectious Disease Prevention Immune System Regulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 1080400 MR: - FA: 1.46 million FAN: 1080400	D: 2025-07-18 FD: 2025-07-18	2 investors

Seed Latest

2025-07-18

$1.1M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Abdelahhad Barbour

CEO Co-Founder and Director

M

Michael Glogauer

CSO Co-Founder and Director

R

Ruthie Glogauer

Operations Manager

M

Mitchell Callaghan

Bioinformatician

K

Kelly Choi

Research Assistant

C

Cara Marks

Research Associate

View 10 more team members with Pro

Unlock Full Team Directory

Recent News